Literature DB >> 26479980

Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement.

A M Cornelison1, R M Saliba1, A Afrough1, Y Dinh1, Y Nieto1, Q Bashir1, N Shah1, S Parmar1, C Hosing1, U Popat1, E Shpall1, R Champlin1, M H Qazilbash1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26479980     DOI： 10.1038/bmt.2015.242

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Martha Q Lacy; Jerry A Katzmann; S Vincent Rajkumar; Roshini S Abraham; Suzanne R Hayman; Shaji K Kumar; Raynell Clark; Robert A Kyle; Mark R Litzow; David J Inwards; Stephen M Ansell; Ivana M Micallef; Luis F Porrata; Michelle A Elliott; Patrick B Johnston; Philip R Greipp; Thomas E Witzig; Steven R Zeldenrust; Stephen J Russell; Dennis Gastineau; Morie A Gertz
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

2.  Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis.

Authors:  M A Gertz; M Q Lacy; J A Lust; P R Greipp; T E Witzig; R A Kyle
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

4.  Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Authors:  R L Comenzo; E Vosburgh; R H Falk; V Sanchorawala; J Reisinger; S Dubrey; L M Dember; J L Berk; G Akpek; M LaValley; C O'hara; C F Arkin; D G Wright; M Skinner
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

5.  Outcome in renal Al amyloidosis after chemotherapy.

Authors:  Jennifer H Pinney; Helen J Lachmann; Loveleen Bansi; Ashutosh D Wechalekar; Janet A Gilbertson; Dorota Rowczenio; Prayman T Sattianayagam; Simon D J Gibbs; Emanuela Orlandi; Nancy L Wassef; Arthur R Bradwell; Philip N Hawkins; Julian D Gillmore
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

6.  High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Authors:  Jolanta B Perz; Stefan O Schonland; Michael Hundemer; Arnt V Kristen; Thomas J Dengler; Martin Zeier; Reinhold P Linke; Anthony D Ho; Hartmut Goldschmidt
Journal:  Br J Haematol       Date:  2004-12       Impact factor: 6.998

7.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

8.  High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Authors:  Martha Skinner; Vaishali Sanchorawala; David C Seldin; Laura M Dember; Rodney H Falk; John L Berk; Jennifer J Anderson; Carl O'Hara; Kathleen T Finn; Caryn A Libbey; Janice Wiesman; Karen Quillen; Niall Swan; Daniel G Wright
Journal:  Ann Intern Med       Date:  2004-01-20       Impact factor: 25.391

9.  A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?

Authors:  Nelson Leung; Siobhan V Glavey; Shaji Kumar; Angela Dispenzieri; Francis K Buadi; David Dingli; Martha Q Lacy; Suzanne R Hayman; John A Lust; Stephen J Russell; Steven R Zeldenrust; S Vincent Rajkumar; Morie A Gertz
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

10.  Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.

Authors:  Xianghua Huang; Qingwen Wang; Wencui Chen; Caihong Zeng; Zhaohong Chen; Dehua Gong; Haitao Zhang; Zhihong Liu
Journal:  BMC Med       Date:  2014-01-06       Impact factor: 8.775
View more
  1 in total

1.  Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.

Authors:  S Y Lee; R S Meehan; D C Seldin; J M Sloan; K Quillen; A Shelton; D Brauneis; V Sanchorawala
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.